Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018799 (heart disease)
 34,133 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Clinical observation suggested an association between an increased cardiothoracic ratio (CT) and growth retardation (IUGR) in the premature neonate. To investigate this hypothesis, a case-control study was performed. Study subjects included 23 cases (IUGR) and 55 control (appropriate for gestational age [AGA]) premature infants with birthweights 2000 gm or less; Apgar scores greater than 5 at 5 minutes; no congenital heart disease; no polycythemia; no toxoplasmosis, rubella, cytomegalovirus, or herpes infection. In random order, the first chest radiograph of each infant (less than 24 hours) was reviewed by a single radiologist, unaware of the infant's growth status. The CT ratio was computed after measuring the widest internal width of the bony thorax and the cardiac diameter. Mean birthweight (+/- 1 SD) of the IUGR infants was 1161 +/- 289 g and of AGA infants was 1401 +/- 401 g (p less than 0.002); the mean gestational ages (+/- 1 SD) were 33.2 +/- 2.8 and 30.8 +/- 2.5 weeks (p less than 0.001). Mean CT for IUGR infants was 0.57 +/- 0.07 (+/- 1 SD) versus AGA infants, 0.51 +/- 0.04 (+/- 1 SD), p less than 0.001. When the infants were stratified by growth status and CT ratio, 11 of 23 IUGR and 1 of 55 AGA infants had an increased CT ratio p less than 0.0001. When birthweight and gestational age were covaried, growth status remained the best predictor of CT, p = 0.005. There is a strong association of increased CT and growth retardation in premature infants with birthweights 2000 gm or less.
 ...
PMID:Association of increased cardiothoracic ratio and intrauterine growth retardation. 198 63

Interventional cardiac catheterization offers increased therapeutic options to many patients with congenital heart disease. Over the past year encouraging results have been reported in hundreds of patients with interatrial communications, patent ductus arteriosus, and pulmonary artery stenosis requiring stenting. The Amplatzer (AGA Medical Corporation, Golden Valley, MN, USA) family of atrial septal, ventricular septal, and ductus occluding devices shows particular promise. Other studies support the efficacy and safety of established procedures such as balloon valvuloplasty and coarctation angioplasty. In some areas, such as transcatheter perforation of atretic pulmonary valves and endovascular stenting for coarctation of the aorta, our technical abilities may be advancing faster than our understanding of the ultimate clinical impact of our treatment. As interventional cardiac catheterization procedures continue to develop, they must be evaluated carefully against alternative treatments.
 ...
PMID:Interventional cardiac catheterization advances in nonsurgical approaches to congenital heart disease. 1055 95

Intracardiac shunts, such as atrial septal defects (ASDs), patent foramen ovales (PFOs), and ventricular septal defects (VSDs), are common forms of congenital or acquired heart disease. Traditional treatment has consisted of surgical closure. Transcatheter closure using implantable devices is now an alternative approach to the treatment of these lesions. Transcatheter closure offers advantages over surgical closure: 1) it is less invasive, resulting in shorter recovery times, less hospital time, and no scarring; 2) it avoids the deleterious neurocognitive effects of cardiopulmonary bypass; 3) it avoids the proarrhythmic effects of atrial or ventricular incisions; and 4) it is potentially less costly. Device closure of secundum ASDs is the procedure of choice. Device closure of PFOs can be performed under humanitarian device exemption (HDE) guidelines, although the indications for this procedure and its effectiveness compared with medical management remain controversial. Ongoing studies are addressing these issues. Transcatheter closure of muscular VSDs is an alternative to surgical treatment, especially for apical defects or those anterior to the moderator band. The CardioSEAL device (NMT Medical, Boston, MA) has HDE status for this purpose and the Amplatzer muscular VSD device (AGA Medical Corp., Golden Valley, MN) is being reviewed by the US Food and Drug Administration for market approval. Phase 1 investigations are underway for device closure of perimembranous VSDs using the Amplatzer perimembranous VSD device (AGA Medical Corp.). Until more data are available, surgical closure of perimembranous VSDs is still the procedure of choice. Closure of postinfarct VSDs can also be accomplished using intracardiac devices; however, this remains a high-risk procedure. Early experience compares favorably with surgical closure. Transcatheter device closure of intracardiac defects is a relatively new procedure. Long-term data for these procedures are currently lacking and, therefore, recommendations regarding the use of these devices will continue to evolve with time.
 ...
PMID:Transcatheter Closure of Intracardiac Shunts. 1532 17

The natural history of congenital heart disease (CHD) with left to right shunt and high pulmonary blood flow, is characterized by development of severe Pulmonary Artery Hypertension (PAH); this condition usually contraindicates any type of surgical or interventional cardiac correction because of bad results. We here report the case of an adult patient with a patent ductus arteriosus and severe PAH, treated uneventfully with a staged combined therapy: Bosentan for 3 months and then percutaneous closure with amplatzer duct occluder (AGA Med. Co. Golden Valley, MN). The patient showed a dramatic improvement both of pulmonary hemodynamics and functional capacity at 8 months follow up confirming the efficacy of pulmonary vasodilator therapy in PAH associated to congenital heart disease.
 ...
PMID:Combined endothelin receptor antagonist and transcatheter interventional therapy of patent ductus arteriosus with severe pulmonary artery hypertension. 1687 49

Symptomatic patients with penetrating atherosclerotic ulcers of the descending thoracic aorta have traditionally been treated by using an open surgical repair. The emergence of thoracic aortic stent-graft technologies has introduced a less invasive treatment option, which often involves covering excess portions of a normal aorta with stent-graft material. We describe the mid-term follow-up of a patient with a symptomatic penetrating atherosclerotic ulcer of the descending thoracic aorta treated with an Amplatzer septal occluder device (AGA Medical Corp, Plymouth, MN), which is typically used for structural heart disease.
 ...
PMID:Closure of a penetrating ulcer of the descending aorta using an Amplatzer occluder. 1969 78

We report the case of a 30 year-old male with congenitally corrected transposition of the great arteries, atrial, and ventricular septal defects (VSD), and pulmonary stenosis. He previously underwent three palliative surgical procedures before undergoing intracardiac repair at age 20 with a left ventricular to pulmonary artery (LV-PA) conduit, VSD closure, and replacement of the systemic atrioventricular valve. A residual VSD was noted postoperatively. He did well for approximately 10 years when he started becoming more breathless with daily activities and was noted to have a resting room air oxygen saturation of 85%. Despite increased diuretic therapy he continued to deteriorate and was ultimately admitted to the hospital in florid right and left heart failure with recurrent atrial fibrillation. Catheterization revealed pulmonary hypertension (pulmonary artery pressure = 80/17 mm Hg), moderate conduit stenosis, severe pulmonic regurgitation, and oxygen saturation of 75%. Calculated shunt fraction (Qp : Qs) was 1.3:1. He was referred for surgical intervention, specifically, LV-PA conduit replacement, oversewing of the pulmonic valve, VSD closure, and pacemaker placement. Intraoperatively, the VSD could not be closed despite multiple attempts through various approaches. Therefore, perventricular VSD closure using two Amplatzer septal occluders (AGA Medical, Golden Valley, MN) was performed in the operating room with the chest open off cardiopulmonary bypass. Following deployment, the residual shunt was small and the inferior vena cava-to-pulmonary artery saturation step-up was only 4%. The left ventricular systolic pressure decreased to one half systemic. This case highlights the utility and efficacy of a hybrid approach in the treatment of complex congenital heart disease.
 ...
PMID:Perventricular closure of a large ventricular septal defect in congenitally corrected transposition of the great arteries. 2013 60

Persistence of the ductus arteriosus (DA), connecting the aorta to the pulmonary artery, after birth leads to a congenital heart disease known as Patent Ductus Arteriosus (PDA). The objective of this study was to propose a new intraductal design for PDA occlusion and determine the efficacy of the new device by means of an in vitro mechanical evaluation. A novel intraductal design device called the Novel design 36 (ND36) was proposed, fabricated and tested. Mechanical tests included tests to determine the mechanical characteristics, force-displacement characteristics, stiffness, device slenderization, minimum diameter attained, insertion force required to pull device at site and lateral pressure exerted on the PDA walls. Comparative analysis was carried out with the Amplatzer Duct Occluder (AGA Medical Corporation, Golden Valley, MN). The results showed that the ND36 when fully stretched was shorter than the ADO implying an easier in vivo movement. The minimum diameter attained by ND36 is 2.52 mm which is compatible with standard catheter bores of 6-8 Fr (2-2.7 mm) bore sizes. A new setup was devised in order to carry out comparative lateral pressure measurements between the ND36 and ADO. The results showed that the ND36 exerted a pressure of 10 KPa (=75 mm Hg) and the ADO exerted 80 KPa (=600 mm Hg) over the walls of the tubes which is a physiologically promising result for the ND36 as it shows that the ND36 would exert lesser stress on the walls of the duct. The results suggest that the novel intraductal design (ND36) would prove to be a safer, reliable and effective device for PDA occlusion.
 ...
PMID:In vitro evaluation of mechanical characteristics of a novel Patent Ductus Arteriosus (PDA) occlusion device with a new lateral pressure measurement study. 2069 17

Aneurysms of sinuses of Valsalva (ASOV) are thin-walled saccular or tubular outpouchings of the aortic sinuses, which can be either congenital or acquired. They can rupture into heart chambers, the pulmonary artery, or the pericardial space (Perloff, Clinical recognition of congenital heart disease, [8]). This report presents a rare case of a patient with treated infective endocarditis who had a patent ductus arteriosus (PDA), a coronary cameral fistula, and a ruptured ASOV (RASOV) into the left ventricle (LV). Successful transcatheter closure of the ruptured ASOV and the other two lesions was performed using three Amplatzer duct occluders (AGA Medical Corporation, Golden Valley, MN, USA).
 ...
PMID:Transcatheter closure of ruptured sinus of valsalva aneurysm into the left ventricle: a retrograde approach. 2227 88